Rhinomed : CEO presentation to 2021 AGM

onal use only

ANNUAL GENERAL

MEETING

WEARABLE NASAL TECHNOLOGY PLATFORM

19 NOVEMBER 2021

IMPORTANT NOTICE AND DISCLAIMER

You must read the following no3ces before reading or making any use of this document or any informa3on contained in this document. By con3nuing to read, use or otherwise act on this document, you agree to be bound by the following terms and

condi3ons, including any modifica3ons to them. The informa3on in this document has been prepared in good faith by Rhinomed Limited ACN 107 903 159 (Rhinomed). Rhinomed has prepared this document based on informa3on available to it to date. No representa3on or warranty, express or implied, is made by any person as to the fairness, accuracy, completeness or correctness of the informa3on, opinions and conclusions contained in this document or any other informa3on provided by

Rhinomed, its respec3ve affiliates or related bodies corporate (as that term is defined in the Corpora3ons Act 2001 (Cth) (Corpora3ons Act) or their respec3ve officers, employees, directors, partners, representa3ves, agents, consultants or advisers (each a Limited Party and together, the Limited Par3es) or any other person otherwise provides to you. To the maximum extent permiPed by law, neither Rhinomed, their respec3ve affiliates or related bodies corporate accepts any liability including, without limita3on, any liability arising from fault, negligence or omission on the part of any person, for any loss, costs or damage arising from the use of this document or its contents or otherwise arising in connec3on with it. This includes for any

indirect, incidental, consequen3al, special or economic loss or damage (including without limita3on, any loss of profit or an3cipated profit, fines or penal3es, loss of business, or an3cipated savings, loss of use, business interrup3on or loss of goodwill, bargain or opportuni3es). This document has not been lodged with ASIC, or otherwise.

Summary informa8on

This document contains summary informa3on about Rhinomed and its ac3vi3es which is current as at the date of this document, unless otherwise indicated. The informa3on in this document remains subject to change without no3ce, and Rhinomed is not responsible for upda3ng, nor does it undertake to update, it. This presenta3on should be read in conjunc3on with Rhinomed's periodic and con3nuous disclosure announcements lodged with the Australian Securi3es Exchange, which are available at hPps://www.rhinomed.global/investor-informa3on/ or www.asx.com.au.

Risk Factors

An investment in Rhinomed securi3es is subject to known and unknown risks, a number of which are beyond the control of Rhinomed. Rhinomed does not guarantee any par3cular rate of return or the performance, nor does it guarantee the repayment of capital from Rhinomed or any par3cular tax treatment. When making their investment decision prospec3ve investors should make their own enquiries and inves3ga3ons regarding all informa3on in this document, including but not limited to the assump3ons, uncertain3es and con3ngencies which may affect future opera3ons of Rhinomed and the impact that different future outcomes may have on Rhinomed.

No Liability

The informa3on contained in this document has been prepared in good faith by Rhinomed however no guarantee representa3on or warranty expressed or implied is or will be made by any person (including Rhinomed and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, es3mates, op3ons, conclusions or other informa3on contained in this document.

To the maximum extent permiPed by law, Rhinomed and its affiliates and their directors, officers employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limita3on, any liability arising out of fault or

negligence, for any loss arising from the use of or reliance on informa3on contained in this document including representa3ons or warran3es or in rela3on to the accuracy or completeness of the informa3on, statements, opinions, forecasts, reports
r ther maPers, express or implied, contained in, arising
onlyut of or derived from, or for omissions from, this document including, without limita3on, any financial informa3on, any es3mates or projec3ons and any other financial informa3on derived therefrom. Statements in this document are made only as
of the date of this document unless otherwise stated and the informa3on in this document remains subject to change without no3ce. No responsibility or liability is assumed by Rhinomed or any of its affiliates for upda3ng any informa3on in this
document or to inform any recipient of any new or more accurate informa3on or any errors or mis-descrip3ons of which Rhinomed and any of its affiliates or advisers may become aware.
use
Forward Looking statements
This document contains certain forward-looking statements, rela3ng to Rhinomed Limited's (Rhinomed) business which can be iden3fied by the use of forward looking terminology such as "promising," "plans," "an3cipated," "will," "project,"
"b	li ve," "forecast," "expected," "es3mated," "targe3ng," "aiming," "set to," "poten3al," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions or by express or implied discussions regarding
pot	n3al filings or marke3ng approvals, or poten3al future sales of the company's technologies and products.

Such forward-looking statements involve known and unknown risks, uncertain3es and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such

tatements. There can be no assurance that any exis3ng or future regulatory filings will sa3sfy any specific health authority and other health authori3es requirements regarding any one or more product or technology nor can there any assurance that uch products or technologies will be approved by any health authori3es for sale in any markets or that they will reach any par3cular level of sales.

In par3cular, management's expecta3ons regarding the approval and commercializa3on of the technology could be affected by, among other things, unexpected clinical trial results, including addi3onal analysis of exis3ng clinical data, and new clinical data; unexpected regulatory ac3ons or delays, or government regula3on generally; our ability to obtain or maintain patent or other proprietary intellectual property protec3on; compe33on in general; government, industry, and general public pricing pressures; and addi3onal factors that involve significant risks and uncertain3es about our products, technology, financial result, and business prospects.

Sho ld one of more of these risks or uncertain3es materialize, or should underlying assump3ons prove incorrect, actual results may vary materially from those described herein as an3cipated, believed, es3mated or expected.

Rhinomed Is providing this informa3on as of the date of this presenta3on and does not assume any obliga3on to update any forward-looking statements contained in this document as a result of new informa3on, future events or developments or otherwise.

Not Financial Product Advice

This document does not it cons3tute financial product advice or take into account your investment objec3ves, taxa3on situa3on, financial situa3on or needs. This document consists purely of factual informa3on and does not involve or imply a

recommenda3on of a statement of opinion in respect of whether to buy, sell or hold a financial product. An investment in Rhinomed is considered to be specula3ve in nature. Before making any investment decision in connec3on with any acquisi3on of securi3es, investors should consult their own legal, tax and/or financial advisers in rela3on to the informa3on in, and ac3on taken on the basis of, this document.

Copyright

The informa3on contained within this document is copyright by Rhinomed 2021

WEARABLE NASAL TECHNOLOGY	1
onal

RHINOMED CORPORATE OVERVIEW

ASX: RNO; OTCQB: RHNMF

• Melbourne, Australia based medical device company specialising in novel wearable nasal medical technology.

only	Our novel medical device platform technology has applications in
•
	consumer health, diagnostics and nasal drug delivery
•	Our existing CE Mark, FDA and TGA registered nasal products have been
	worn comfortably and safely since 2016 with over 30 million nightly
	user experiences.
•	Extensive IP portfolio - including over 60 patents and over 50 design
	patents.
•	This year we welcomed medical pioneer Prof John McBain to the board.
use
Board and Management
	Mr Ron Dewhurst	Chairman
	Mr Michael Johnson	CEO and Managing Director
	Assoc Prof. John McBain	Non-Executive Director
	Mr Brent Scrimshaw	Non-Executive Director
	Dr Eric Knight	Non-Executive Director
onal	Mr Sean Slattery	CFO and Company Secretary
WEARABLE NASAL TECHNOLOGY

Key Metrics

Market Cap	~AU$70m
Current Stock price	A$0.27
Shares on issue	254 m
Top 20 Investors	77%

Top Investors

Mr Whitney George (US)	40.0%
Prof John McBain (Aust)	17.9%
Mr Ron Dewhurst (Aust)	5.8%
Citicorp Nominees	2.2%
HSBC Custody Nominees	2.1%

2

DELIVERED TOP LINE GROWTH IN A PANDEMIC YEAR

NEW TECHNOLOGY LINES ALREADY IMPACTING REVENUES IN FY22

use only

$3,286

Revenue

FY19

$ '000

$4,203

$3,895

$3,565

$1,723

Revenue	Revenue	Revenue	Sales Orders
FY20	FY21	FY22 Q1	FY22Q1

• Continued growth as we build our presence in global pharmacy
• Revenues continue to grow despite pandemic effect on pharmacy foot traffic
• Revenues + 9% PCP
• Gross margins maintained ~ 70%
• Record FY22 Q1 revenues
• New Rhinoswab program released in FY22 Q1
• Already delivering revenues and strong order book
• Sales order book in FY22Q1 exceeds entire FY21 Revenues

onal	3
WEARABLE NASAL TECHNOLOGY

KEY HIGHLIGHTS IN CONSUMER HEALTH

STRONG PROGRESS ACROSS THE BUSINESS

only
#1 INTERNAL NASAL
	DILATOR
	In the USA
use	+ 117%
	Shipments to Amazon US in last
	52 weeks
onal

WEARABLE NASAL TECHNOLOGY

+ 210%

Shipments to USA in last 26

weeks

3 x

Growth in Amazon US revenues

over 2020

+ 46%

Shipments to US in last 52

weeks

+ 15%

UK sales growth PCP

4